glioma

Overview

Glioma is a broad category of primary central nervous system tumors arising from glial lineage cells in the brain and spinal cord. It includes biologically and clinically diverse entities, ranging from lower-grade diffuse gliomas to highly aggressive forms such as glioblastoma. In recent research, glioma is consistently described as a highly malignant, invasive, and recurrent brain cancer with poor prognosis, substantial therapeutic resistance, and a strongly immunosuppressive tumor microenvironment.

Molecularly, glioma research increasingly focuses on alterations such as IDH mutation status, BRAF alterations, MET/c-Met signaling, PI3K/AKT pathway activity, ferroptosis-related mechanisms, immune evasion, and metabolic reprogramming, including methionine and glucose metabolism. The disease is also a major target for advanced imaging, radiogenomics, liquid biopsy, and precision oncology approaches aimed at improving diagnosis, molecular classification, prognosis, and treatment selection.

Role in Recent Research

Recent publications portray glioma as a central model for studying tumor aggressiveness, immune suppression, and precision therapy. Several studies emphasized its poor prognosis, high invasiveness, and recurrence, including work on prognostic gene signatures, immune-related signatures, and metabolic signatures. One study reported that glioma is characterized by an immunosuppressive tumor microenvironment that contributes to therapeutic resistance, motivating the development of a MET-associated immune prognostic signature to predict survival and guide personalized therapy. Another study examined a glucose metabolism disorder and immune-related gene signature, again underscoring the importance of metabolic and immune features in glioma outcome prediction.

A major theme across the recent literature is molecular stratification. A consensus review on BRAF-altered glioma highlighted that oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In parallel, studies of IDH mutation status and Ki-67 expression used deep learning to support simultaneous prediction from MRI, reflecting the clinical importance of molecular classification in glioma management. Another report focused on CSF ctDNA analysis to guide molecular reclassification of diffuse glioma patients, reinforcing the need for better diagnostic and monitoring strategies. Related work on plasma extracellular vesicles proposed multimodal liquid biopsy biomarkers for glioma diagnosis, while radiogenomic analysis linked MRI features to survival prediction and extracellular matrix remodeling.

Imaging and surgical planning were also prominent. A knowledge-guided 3D MRI segmentation framework was developed for precise and consistent glioma delineation, with direct relevance to surgical planning, radiotherapy targeting, and diagnostic decision-making. A separate study on partial tumor irradiation in a rat glioma model evaluated a PATHY-inspired workflow on a small-animal radiation platform, indicating continued interest in spatially selective radiotherapy strategies. Another minimally invasive resection series included ependymomas/gliomas among deep-seated lesions treated with an integrated camera-port system, showing the role of advanced operative technologies in difficult intracranial tumors.

Therapeutic research in glioma remains broad and mechanistically diverse. Vebreltinib, a novel type I c-Met inhibitor, was described as being developed for non-small cell lung cancer and glioma, reflecting ongoing interest in MET-targeted therapy. Cryptotanshinone was investigated for its effects on glioma cells through the EGFR/ROS pathway and ferroptosis-mediated antitumor activity. Scutellarein was reported to inhibit glioma malignancy via the PI3K/Akt signaling pathway. Other studies examined sorbicillin water fraction from Penicillium flavigenum for anti-proliferative, apoptotic, and neuroinflammatory effects in a glioma model, and another explored the role of methionine concentration in regulating LSD1 acetylation in glioma cells, linking amino acid metabolism to epigenetic regulation.

The tumor microenvironment and immune biology of glioma were also major topics. A consensus statement on microglial and macrophage functions synthesized evidence on tumor-associated microglia/macrophages in glioma progression and therapeutic resistance. Another study proposed a risk model involving MMP9, TLR8, and LILRB2 that drives neutrophil extracellular trap formation and immune evasion. CAR-neutrophils produced in vivo were shown in a syngeneic glioma model to inhibit tumor growth, prolong survival, enhance T cell recruitment and activation, and reduce immunosuppression of myeloid cells. Additional work on syntaphilin suggested effects on invasion, mitochondrial redistribution, and the immune microenvironment, supporting its potential as a prognostic biomarker.

Several studies addressed drug discovery and translational targeting. Angiopep-2-based radiolabeled vectors were evaluated as a blood-brain barrier targeting platform with potential for future glioma-targeted studies. Multiscale analysis using the CANDO platform was applied to discover therapeutic candidates for glioma, and other work used network pharmacology and computer-aided drug design approaches to identify candidate compounds and pathways. These studies collectively reflect the continuing effort to overcome blood-brain barrier delivery constraints and identify actionable molecular vulnerabilities in glioma.

Key Publications

• NEWJul MET-associated immune prognostic signature predicts survival and guides personalized therapy in glioma. (Acta neuropathologica communications, 2026, PMID 42387647): "Glioma is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment (TME) that drives therapeutic resistance."
• Jul PATHY-inspired partial tumor irradiation on a small-animal irradiator: workflow development and first therapeutic evaluation in glioma. (Physics in medicine and biology, 2026, PMID 42173137): "Here, we establish a PATHY-inspired PTI workflow on a Small Animal Radiation Research Platform and evaluate its therapeutic efficacy in a rat glioma model."
• Jul Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants. (Clinical and translational science, 2026, PMID 42348314): "Vebreltinib is a novel, highly selective type I c-Met inhibitor developed for treating non-small cell lung cancer (NSCLC) and glioma."
• Jul Radiolabeled Angiopep-2 Peptide Vector as a Preclinical Platform for Blood-Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice. (Journal of peptide science : an official publication of the European Peptide Society, 2026, PMID 42270414): "These results support DOTA-Angiopep-2 as a versatile platform for radionuclide delivery and a potential candidate for future glioma-targeted studies."
• Jun Assessing the prognostic value of SIL1 in pan-cancer cohorts and its practical application as a biomarker in glioma practice. (BMC cancer, 2026, PMID 42374254): "This study aimed to investigate the clinical significance and biological functions of SIL1 in glioma."
• Jun A multimodal ConvNeXt-Tiny deep learning model for simultaneous prediction of IDH mutation and Ki-67 expression in gliomas. (PloS one, 2026, PMID 42361071): "To construct and validate a multi-task deep learning model based on ConvNeXt-Tiny for synchronous prediction of isocitrate dehydrogenase (IDH) mutation status and Ki-67 expression level in gliomas."
• Jun Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. (Neurochemical research, 2026, PMID 42348047): "To investigate the regulatory effects of cryptotanshinone (CTS) on the biological behavior of glioma cells and its underlying molecular mechanisms, with a particular focus on the role of the epidermal growth factor receptor/reactive oxygen species (EGFR/ROS) pathway in ferroptosis-mediated antitumor activity."
• Jun GL-Net: A knowledge-guided Gaussian-gated and layered refinement network for 3D MRI segmentation of brain gliomas. (PloS one, 2026, PMID 42329889): "The proposed framework shows strong clinical potential for precise and consistent glioma delineation, providing valuable support for surgical planning, radiotherapy targeting, and diagnostic decision-making in clinical workflows."
• Apr Scutellarein inhibits the malignancy of gliomas by modulating the PI3K/AKT signaling pathway. (Biochemical and biophysical research communications, 2026, PMID 41966746): "Glioma is the most common primary intracranial tumor and is characterized by poor prognosis and high invasiveness."
• Jun BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. (Neuro-oncology, 2026, PMID 42261252): "Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics."